PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy

Trial Profile

PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Levonorgestrel (Primary) ; Medroxyprogesterone (Primary)
  • Indications Endometriosis; Pelvic pain
  • Focus Therapeutic Use
  • Acronyms PRE-EMPT
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Sep 2019 to 30 Jun 2021.
    • 11 Dec 2015 Accrual to date is 37% according to the United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 19% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top